Tumor necrosis factor-α in the pathogenesis and treatment of cancer

The critical pathogenic role of tumor necrosis factor (TNF)α in inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease is well established. The role played by TNFα in both the treatment and pathogenesis of cancer remains less understood. Recent advances help to create a f...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in pharmacology 2004-08, Vol.4 (4), p.314-320
Main Authors: Anderson, G Mark, Nakada, Marian T, DeWitte, Mark
Format: Article
Language:English
Subjects:
Animals
Humans
Neoplasms - etiology
Neoplasms - therapy
Signal Transduction
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - physiology
Tumor Necrosis Factor-alpha - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 320
container_issue 4
container_start_page 314
container_title Current opinion in pharmacology
container_volume 4
creator Anderson, G Mark
Nakada, Marian T
DeWitte, Mark
description The critical pathogenic role of tumor necrosis factor (TNF)α in inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease is well established. The role played by TNFα in both the treatment and pathogenesis of cancer remains less understood. Recent advances help to create a framework for understanding seemingly paradoxical effects of TNFα as both an anti-tumour agent and a mediator of tumour growth. High pharmacological doses of TNFα combined with chemotherapy can regress otherwise intractable tumours, and efforts continue to optimize delivery to avoid severe toxicities. Mounting evidence demonstrates that pathophysiological concentrations of endogenous TNFα act to promote tumour genesis and growth. The cellular and molecular pathways mediating these phenomena are starting to be clarified. Current data support the continued development of both TNFα and anti-TNFα therapy for clinical treatment of cancers in distinct settings.
doi_str_mv 10.1016/j.coph.2004.04.004
format article
fullrecord <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmed_primary_15251122</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1471489204000943</els_id><sourcerecordid>S1471489204000943</sourcerecordid><originalsourceid>FETCH-LOGICAL-e260t-74babb8d7bef8eb6cc5e6b8520dbe652bd8b635fdf2c05fb679e85e51dd318313</originalsourceid><addsrcrecordid>eNo1kNtKAzEURYMotlZ_wAfJD8yYyySTgi9Sr1DwpT6HXE5sinMhkwp-lj_iNzlDLWw4B87msPdC6JqSkhIqb3el6_ptyQipykmkOkFzWtW0qJY1Pz3uaslm6GIYdoRQwXl9jmZUMEEpY3P0sNk3XcItuNQNccDBuNyl4vcHxxbnLeDe5G33AS1MV9N6nBOY3ECbcRewM62DdInOgvkc4Op_LtD70-Nm9VKs355fV_frApgkuagra6xVvrYQFFjpnABplWDEW5CCWa-s5CL4wBwRwcp6CUqAoN5zqjjlC3Rz-NvvbQNe9yk2Jn3rY53RcHcwwJjiK0LSg4swRvQxgcvad1FToid6eqcnenqipyeRiv8BCBVjvQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tumor necrosis factor-α in the pathogenesis and treatment of cancer</title><source>ScienceDirect Freedom Collection</source><creator>Anderson, G Mark ; Nakada, Marian T ; DeWitte, Mark</creator><creatorcontrib>Anderson, G Mark ; Nakada, Marian T ; DeWitte, Mark</creatorcontrib><description>The critical pathogenic role of tumor necrosis factor (TNF)α in inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease is well established. The role played by TNFα in both the treatment and pathogenesis of cancer remains less understood. Recent advances help to create a framework for understanding seemingly paradoxical effects of TNFα as both an anti-tumour agent and a mediator of tumour growth. High pharmacological doses of TNFα combined with chemotherapy can regress otherwise intractable tumours, and efforts continue to optimize delivery to avoid severe toxicities. Mounting evidence demonstrates that pathophysiological concentrations of endogenous TNFα act to promote tumour genesis and growth. The cellular and molecular pathways mediating these phenomena are starting to be clarified. Current data support the continued development of both TNFα and anti-TNFα therapy for clinical treatment of cancers in distinct settings.</description><identifier>ISSN: 1471-4892</identifier><identifier>EISSN: 1471-4973</identifier><identifier>DOI: 10.1016/j.coph.2004.04.004</identifier><identifier>PMID: 15251122</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Humans ; Neoplasms - etiology ; Neoplasms - therapy ; Signal Transduction ; Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors ; Tumor Necrosis Factor-alpha - physiology ; Tumor Necrosis Factor-alpha - therapeutic use</subject><ispartof>Current opinion in pharmacology, 2004-08, Vol.4 (4), p.314-320</ispartof><rights>2004 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,783,787,27936,27937</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15251122$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anderson, G Mark</creatorcontrib><creatorcontrib>Nakada, Marian T</creatorcontrib><creatorcontrib>DeWitte, Mark</creatorcontrib><title>Tumor necrosis factor-α in the pathogenesis and treatment of cancer</title><title>Current opinion in pharmacology</title><addtitle>Curr Opin Pharmacol</addtitle><description>The critical pathogenic role of tumor necrosis factor (TNF)α in inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease is well established. The role played by TNFα in both the treatment and pathogenesis of cancer remains less understood. Recent advances help to create a framework for understanding seemingly paradoxical effects of TNFα as both an anti-tumour agent and a mediator of tumour growth. High pharmacological doses of TNFα combined with chemotherapy can regress otherwise intractable tumours, and efforts continue to optimize delivery to avoid severe toxicities. Mounting evidence demonstrates that pathophysiological concentrations of endogenous TNFα act to promote tumour genesis and growth. The cellular and molecular pathways mediating these phenomena are starting to be clarified. Current data support the continued development of both TNFα and anti-TNFα therapy for clinical treatment of cancers in distinct settings.</description><subject>Animals</subject><subject>Humans</subject><subject>Neoplasms - etiology</subject><subject>Neoplasms - therapy</subject><subject>Signal Transduction</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><subject>Tumor Necrosis Factor-alpha - physiology</subject><subject>Tumor Necrosis Factor-alpha - therapeutic use</subject><issn>1471-4892</issn><issn>1471-4973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNo1kNtKAzEURYMotlZ_wAfJD8yYyySTgi9Sr1DwpT6HXE5sinMhkwp-lj_iNzlDLWw4B87msPdC6JqSkhIqb3el6_ptyQipykmkOkFzWtW0qJY1Pz3uaslm6GIYdoRQwXl9jmZUMEEpY3P0sNk3XcItuNQNccDBuNyl4vcHxxbnLeDe5G33AS1MV9N6nBOY3ECbcRewM62DdInOgvkc4Op_LtD70-Nm9VKs355fV_frApgkuagra6xVvrYQFFjpnABplWDEW5CCWa-s5CL4wBwRwcp6CUqAoN5zqjjlC3Rz-NvvbQNe9yk2Jn3rY53RcHcwwJjiK0LSg4swRvQxgcvad1FToid6eqcnenqipyeRiv8BCBVjvQ</recordid><startdate>20040801</startdate><enddate>20040801</enddate><creator>Anderson, G Mark</creator><creator>Nakada, Marian T</creator><creator>DeWitte, Mark</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20040801</creationdate><title>Tumor necrosis factor-α in the pathogenesis and treatment of cancer</title><author>Anderson, G Mark ; Nakada, Marian T ; DeWitte, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e260t-74babb8d7bef8eb6cc5e6b8520dbe652bd8b635fdf2c05fb679e85e51dd318313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Humans</topic><topic>Neoplasms - etiology</topic><topic>Neoplasms - therapy</topic><topic>Signal Transduction</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><topic>Tumor Necrosis Factor-alpha - physiology</topic><topic>Tumor Necrosis Factor-alpha - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anderson, G Mark</creatorcontrib><creatorcontrib>Nakada, Marian T</creatorcontrib><creatorcontrib>DeWitte, Mark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Current opinion in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anderson, G Mark</au><au>Nakada, Marian T</au><au>DeWitte, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor necrosis factor-α in the pathogenesis and treatment of cancer</atitle><jtitle>Current opinion in pharmacology</jtitle><addtitle>Curr Opin Pharmacol</addtitle><date>2004-08-01</date><risdate>2004</risdate><volume>4</volume><issue>4</issue><spage>314</spage><epage>320</epage><pages>314-320</pages><issn>1471-4892</issn><eissn>1471-4973</eissn><abstract>The critical pathogenic role of tumor necrosis factor (TNF)α in inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease is well established. The role played by TNFα in both the treatment and pathogenesis of cancer remains less understood. Recent advances help to create a framework for understanding seemingly paradoxical effects of TNFα as both an anti-tumour agent and a mediator of tumour growth. High pharmacological doses of TNFα combined with chemotherapy can regress otherwise intractable tumours, and efforts continue to optimize delivery to avoid severe toxicities. Mounting evidence demonstrates that pathophysiological concentrations of endogenous TNFα act to promote tumour genesis and growth. The cellular and molecular pathways mediating these phenomena are starting to be clarified. Current data support the continued development of both TNFα and anti-TNFα therapy for clinical treatment of cancers in distinct settings.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15251122</pmid><doi>10.1016/j.coph.2004.04.004</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1471-4892
ispartof Current opinion in pharmacology, 2004-08, Vol.4 (4), p.314-320
issn 1471-4892
1471-4973
language eng
recordid cdi_pubmed_primary_15251122
source ScienceDirect Freedom Collection
subjects Animals
Humans
Neoplasms - etiology
Neoplasms - therapy
Signal Transduction
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - physiology
Tumor Necrosis Factor-alpha - therapeutic use
title Tumor necrosis factor-α in the pathogenesis and treatment of cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-11T18%3A23%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20necrosis%20factor-%CE%B1%20in%20the%20pathogenesis%20and%20treatment%20of%20cancer&rft.jtitle=Current%20opinion%20in%20pharmacology&rft.au=Anderson,%20G%20Mark&rft.date=2004-08-01&rft.volume=4&rft.issue=4&rft.spage=314&rft.epage=320&rft.pages=314-320&rft.issn=1471-4892&rft.eissn=1471-4973&rft_id=info:doi/10.1016/j.coph.2004.04.004&rft_dat=%3Celsevier_pubme%3ES1471489204000943%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e260t-74babb8d7bef8eb6cc5e6b8520dbe652bd8b635fdf2c05fb679e85e51dd318313%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/15251122&rfr_iscdi=true